Methods for the treatment of patients with HER2-positive, HER2-amplified and/or HER2-mutated advanced cancer by administration of pertuzumab plus trastuzumab are disclosed. In one aspect, the cancer is advanced HER2-positive, HER2-amplified and/or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer. In another aspect, the cancer is HER2-positive, HER2-amplified and/or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer that is refractory to one or more other treatment regimens.所揭示者係用於藉由投與培妥珠單抗加曲妥珠單抗治療具有HER2陽性、HER2擴增、及/或HER2突變晚期癌症之方法。在一個態樣中，該癌症係晚期HER2陽性、HER2擴增、及/或HER2突變結腸直腸癌、膽道癌、膀胱癌、泌尿上皮癌、唾液腺癌、肺癌、胰腺癌、卵巢癌、前列腺癌、或皮膚癌。在另一態樣中，該癌症係一或多個其他治療方案所難治的HER2陽性、HER2擴增、及/或HER2突變結腸直腸癌、膽道癌、膀胱癌、泌尿上皮癌、唾液腺癌、肺癌、胰腺癌、卵巢癌、前列腺癌、或皮膚癌。
